上市决策领域
Formulation & Scale-Up
Commercially relevant formulation, format, stability and scale-up considerations for dietary supplement and medical-nutrition programmes.
4
份指南
Formulation & Scale-Up
Navigating Lifecycle Impairment Mechanisms for Dietary Supplements and Functional Foods: From Formulation to Systemic Exposure
Buyers face significant risk from diverse formulation, processing, and physiological mechanisms that measurably impair the identity, potency, release, bioaccessibility, systemic exposure, or safety of dietary supplements and functional foods. This can lead to reduced efficacy and commercial failure if not addressed across the product lifecycle.
Formulation & Scale-Up
Optimizing Multi-Strain Probiotic Formulations: Addressing Viability, Delivery, and Efficacy Challenges
The formulation challenge is preventing significant strain-level viability loss and compromised clinical efficacy in multi-strain probiotics. Buyers must address degradation from moisture, manufacturing, and GI transit.
Formulation & Scale-Up
Optimizing Lipophilic Active Softgels: Managing Oxidation, Stability, and Bioavailability Through Formulation and Packaging
Ensuring the long-term chemical and physical stability, dissolution performance, and oral bioavailability of lipophilic actives in softgels is challenged by complex interactions between fill composition, shell material, packaging, and supply-chain conditions.
上市策略
膳食补充剂制造时间表：从产品简报到首个商业批次的关键路径
买方的主要风险在于未预先明确关键产品、市场及法规参数即盲目承诺上市时间表、功效宣称或配方，进而导致高昂的返工成本或错失市场机遇。
本页没有符合所选主题的指南。请尝试其他标签或清除筛选条件。
EXPLORE RELATED INTELLIGENCE